New York: Johnson & Johnson’s single-dose Covid vaccine produced relatively low levels of antibodies against the delta variant in a study, raising questions about how well the shot will hold up against the strain that accounts for the vast majority of U.S. cases.
The laboratory study, released on the preprint server bioRxiv, hasn’t been published in a peer-reviewed journal and focuses on one key portion of the immune response, called neutralizing antibodies. New York University scientists found that J&J’s vaccine produced roughly five-fold lower levels of the protective antibodies against the delta variant compared to the levels raised against an early coronavirus strain.
The delta variant accounts for 83% of genetically sequenced cases in the U.S., Centers for Disease Control and Prevention Director Rochelle Walensky said Tuesday in a Senate hearing. While two-dose messenger RNA vaccines from Pfizer Inc. and Moderna Inc. also produced fewer antibodies against the highly transmissible delta strain, the reduction was less dramatic, the study found.
Compared to two shots of mRNA vaccines, the single-shot J&J vaccine “showed a more pronounced decrease in neutralizing titer against the variants, raising the potential for decreased protection,” the researchers from NYU researchers said in the study.
One aspect
The study examined only one aspect of protection, J&J said in an email, and didn’t consider long-lasting responses among immune cells stimulated by its vaccine.
“The data do not speak to the full nature of immune protection” from the shot, spokesman Jake Sargent said. J&J’s vaccine has been shown to produce a strong immune response that lasts at least eight months after immunization, he said.
Earlier this month, J&J researchers said their own data indicated that the vaccine neutralizes the delta variant and booster shots weren’t needed.
Study author Nathaniel Landau of NYU Grossman School of Medicine said the results of his study and J&J’s antibody analysis are not totally different. Both found a decreased level of antibodies, he said in an email.
“We just found a greater degree of decrease,” he said. –Bloomberg
Also read: Jeff Bezos travels to edge of space in Blue Origin’s first passenger flight